Welcome to our dedicated page for Fibrogen news (Ticker: FGEN), a resource for investors and traders seeking the latest updates and insights on Fibrogen stock.
FibroGen Inc (NASDAQ: FGEN) is a clinical-stage biopharmaceutical company pioneering novel therapies for oncology and anemia through innovative HIF biology and antibody-drug conjugate research. This page serves as the definitive source for verified FibroGen news and official communications, providing stakeholders with timely updates on clinical developments and corporate milestones.
Investors and industry observers will find essential information including clinical trial results, regulatory submissions, and strategic partnership announcements. Our curated feed includes earnings reports, research publications, and manufacturing updates directly impacting FibroGen's progress in bringing targeted therapies to market.
Key content categories cover advancements in the company's HIF-PH inhibitor programs for anemia management, ADC oncology candidates, and updates from global collaborations. All materials are sourced from primary corporate disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to FibroGen's latest developments. Check regularly for critical updates on pipeline progress, peer-reviewed study data, and market-moving announcements relevant to FGEN shareholders and industry analysts.
FibroGen (FGEN) has completed the enrollment of 73 ambulatory Duchenne muscular dystrophy (DMD) patients in its Phase 3 LELANTOS-2 clinical trial, evaluating pamrevlumab. This study aims to assess the efficacy and safety of pamrevlumab in combination with corticosteroids, focusing on ambulatory function over 52 weeks. Top-line data is expected in the second half of 2023. Pamrevlumab has received Orphan Drug and Fast Track designations from the FDA for DMD treatment. The drug is also in trials for idiopathic pulmonary fibrosis and pancreatic cancer.
FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 PM EDT. A live audio webcast will be available on the company's Investors webpage, with a replay accessible for up to 30 days. FibroGen focuses on developing innovative therapeutics, including pamrevlumab for conditions like idiopathic pulmonary fibrosis and roxadustat for anemia linked to chronic kidney disease. The company is also expanding into immuno-oncology and autoimmune research.
FibroGen reported a strong start in 1Q 2022 with total revenue of $60.8 million, up 58% year-over-year. The successful enrollment in the ZEHPYRUS-1 Phase 3 study for pamrevlumab in idiopathic pulmonary fibrosis and LELANTOS-1 Phase 3 study for Duchenne muscular dystrophy were highlighted. Roxadustat showed significant volume growth in China, with net sales totaling $43.5 million, despite a price reduction. The company reported a net loss of $63.2 million for the quarter, a slight improvement from the previous year, and held $565.4 million in cash as of March 31, 2022.
FibroGen (FGEN) will announce its Q1 2022 financial results on May 9 after market close, followed by a conference call at 5:00 p.m. ET. The call aims to discuss the company's corporate and financial performance in detail. FibroGen focuses on developing first-in-class therapeutics targeting unmet medical needs, with key products under development including pamrevlumab for various conditions such as idiopathic pulmonary fibrosis and roxadustat for anemia related to chronic kidney disease. A replay of the call will be available for seven days.
FibroGen, Inc. (NASDAQ: FGEN) has successfully completed the enrollment of 356 patients in the Phase 3 clinical trial ZEPHYRUS-1, aimed at evaluating pamrevlumab for treating idiopathic pulmonary fibrosis (IPF). This study is double-blind and placebo-controlled, focusing on the change in forced vital capacity (FVC) as the primary endpoint. Topline data is expected in mid-2023. Pamrevlumab is a first-in-class antibody that inhibits connective tissue growth factor (CTGF) and has received Orphan Drug and Fast Track designations from the FDA for IPF, among other indications.
FibroGen, Inc. (NASDAQ: FGEN) reported a revenue increase from $176.3 million in 2020 to $235.3 million in 2021. The company completed the enrollment for the LAPIS Phase 3 study in pancreatic cancer and the LELANTOS-1 Phase 3 study in Duchenne muscular dystrophy. FibroGen's net loss widened to $134.1 million in Q4 2021 from $58.6 million the previous year. Roxadustat achieved $186.1 million in total sales in China for 2021, up from $72.5 million in 2020. The company plans to reduce projected expenses by $100 million annually over the next three years.
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call with investors is scheduled for the same day at 5:00 p.m. ET. This call will provide insights into the company’s corporate and financial performance.
Investors can access the call via the FibroGen website, with a replay available for 7 days post-call. FibroGen focuses on developing therapeutics for unmet medical needs, including treatments for anemia in chronic kidney disease and other conditions.
FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 3:40pm EST. The event's audio webcast will be accessible on the FibroGen Investor webpage, with a replay available for 30 days.
FibroGen focuses on developing innovative therapeutics, including roxadustat for various anemias and pamrevlumab for conditions like idiopathic pulmonary fibrosis and pancreatic cancer. The company has expanded into immuno-oncology and autoimmune research.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference from January 10-13. The session will be available on-demand starting January 10 at 7:00am EST.
Listeners can access the audio webcast via the 'Events & Presentations' section on FibroGen's Investor webpage, with a replay available for 30 days. FibroGen is focused on first-in-class therapeutics, including the development of roxadustat and pamrevlumab for various medical conditions.
FibroGen (FGEN) has extended its partnership with HiFiBiO Therapeutics by exercising an exclusive license for the anti-CCR8 monoclonal antibody program, HFB1011. This agreement involves a $35 million upfront payment plus potential milestones and royalty payments based on net sales. FibroGen gains exclusive global rights to develop products from this program, which targets CCR8, a receptor implicated in tumor immune suppression. The HFB1011 development candidate is expected to enter clinical trials in 2023, reinforcing FibroGen's focus on expanding its immuno-oncology pipeline.
FAQ
What is the current stock price of Fibrogen (FGEN)?
What is the market cap of Fibrogen (FGEN)?
